Feedback / Questions
XS-411 - Xellsmart Biomedical
XS228 - Xellsmart Biomedical
https://www.prnewswire.com/news-releases/xellsmarts-allogeneic-ipsc-derived-cell-therapies-for-parkinsons-disease-and-als-officially-approved-by-the-us-fda-for-phase-i-clinical-trials-302427583.html
Apr 15, 2025
SHARE THIS
Print
Email
More sharing
Reddit
StumbleUpon
Delicious
Next